More tools:Markets·Screener·Research·Chat

Gossamer Bio, Inc. Common Stock (GOSS) Financial Statements

Gossamer Bio, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00MVWLMC1
XNAS · usd
0.18▲ 0.00 (2.62%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.18
Day's Range0.17 – 0.18
52-Week Range0.11 – 3.87
Volume6.8M
Avg Volume25.4M
Share Statistics
Shares Outstanding
Employees162
ExchangeXNAS
Listed2019-02-08
Share count as of August 8, 2026
Loading Income Statement…
Key questions about Gossamer Bio, Inc. Common Stock (GOSS)
What is Gossamer Bio, Inc. Common Stock's Market Cap?
Gossamer Bio, Inc. Common Stock's Market Cap is $87.9M, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's Price / Sales?
Gossamer Bio, Inc. Common Stock's Price / Sales is 1.7×, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's Revenue (TTM)?
Gossamer Bio, Inc. Common Stock's Revenue (TTM) is $53.3M, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's Net Income (TTM)?
Gossamer Bio, Inc. Common Stock's Net Income (TTM) is -$125.2M, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's EBITDA?
Gossamer Bio, Inc. Common Stock's EBITDA is -$166.1M, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's Diluted EPS (TTM)?
Gossamer Bio, Inc. Common Stock's Diluted EPS (TTM) is -0.26, based on as-reported figures from SEC (XBRL) filings.
What is Gossamer Bio, Inc. Common Stock's EBITDA Margin?
Gossamer Bio, Inc. Common Stock's EBITDA Margin is -311.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-19.6%+71.5%+47.1%+40.2%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue382.2%364.6%433.6%469.4%
Loss from operations
% of revenue-282.2%-264.6%-333.6%-369.4%
Other income (expense)
Interest income
Interest expense
Remeasurement of warrant liability———
Remeasurement of derivative liability———
Gain on debt extinguishment———
Other income (loss), net
Total other income, net
Net income (loss)
% of revenue182.9%-275.2%-342.3%-362.7%
Net income (loss) per share, basic (in dollars per share)
Net income (loss) per share, diluted (in dollars per share)